Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Oral Dis ; 24(3): 325-334, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28247977

RESUMEN

Burning mouth syndrome (BMS) is a chronic oral pain syndrome that primarily affects peri- and postmenopausal women. It is characterized by oral mucosal burning and may be associated with dysgeusia, paresthesia, dysesthesia, and xerostomia. The etiology of the disease process is unknown, but is thought to be neuropathic in origin. The goal of this systematic review was to assess the efficacy of the various treatments for BMS. Literature searches were conducted through PubMed, Web of Science, and Cochrane Library databases, which identified 22 randomized controlled trials. Eight studies examined alpha-lipoic acid (ALA), three clonazepam, three psychotherapy, and two capsaicin, which all showed modest evidence of potentially decreasing pain/burning. Gabapentin was seen in one study to work alone and synergistically with ALA. Other treatments included vitamins, benzydamine hydrochloride, bupivacaine, Catuama, olive oil, trazodone, urea, and Hypericum perforatum. Of these other treatments, Catuama and bupivacaine were the only ones with significant positive results in symptom improvement. ALA, topical clonazepam, gabapentin, and psychotherapy may provide modest relief of pain in BMS. Gabapentin may also boost the effect of ALA. Capsaicin is limited by its side effects. Catuama showed potential for benefit. Future studies with standardized methodology and outcomes containing more patients are needed.


Asunto(s)
Antioxidantes/uso terapéutico , Síndrome de Boca Ardiente/tratamiento farmacológico , Clonazepam/uso terapéutico , Moduladores del GABA/uso terapéutico , Ácido Tióctico/uso terapéutico , Aminas/uso terapéutico , Analgésicos/uso terapéutico , Síndrome de Boca Ardiente/terapia , Capsaicina/uso terapéutico , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Gabapentina , Humanos , Dimensión del Dolor , Psicoterapia , Fármacos del Sistema Sensorial/uso terapéutico , Ácido gamma-Aminobutírico/uso terapéutico
2.
Clin Oncol (R Coll Radiol) ; 29(5): 298-306, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28242165

RESUMEN

Anaplastic thyroid cancer, medullary thyroid cancer, primary thyroid lymphoma and primary thyroid sarcoma are rare thyroid cancers that comprise 5-10% of all thyroid malignancies. Unlike well-differentiated thyroid cancers, these malignancies have few treatment options and carry a worse prognosis. The literature surrounding these pathologies is limited, but remains an area of active research. Despite the rarity of these conditions, they remain an important part of the differential diagnosis for any thyroid nodule. Awareness of their presentation, work-up and management is critical for oncologists and head and neck surgeons. The purpose of this article is to provide a broad overview of these malignancies with an emphasis on emerging clinical research and therapies.


Asunto(s)
Antineoplásicos/uso terapéutico , Glándula Tiroides/patología , Neoplasias de la Tiroides/patología , Tiroidectomía/métodos , Manejo de la Enfermedad , Humanos , Oncólogos , Neoplasias de la Tiroides/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA